The collaboration will focus on moving the clinical development of Exebryl-1 though the regulatory process in China and the US.
Exebryl-1 has been shown to inhibit beta-amyloid protein aggregate formation in brain, as well as disaggregate amyloid plaques that are already present. The drug has also shown specificity against tau protein aggregates and may be the first therapeutic targeting beta-amyloid and tau protein associated with this disease.
As per the agreement, ProteoTech will receive an upfront payment, development costs and research funding. Tasly will gain rights for Exebryl-1 for China and ProteoTech will retain rights for the US and the rest of the world.
Besides Exebryl-1 for Alzheimer’s disease treatment, Kirkland, Washington-based ProteoTech is also in late stage pre-clinical development of Synuclere for Parkinson’s disease, Systebryl for Systemic Amyloidosis and is in late stage pre-clinical development for a small peptide called PeptiClere for Alzheimer’s disease.
Tasly’s scope of business includes modern TCM, ethical pharmaceutical and biological medications, healthcare products and functional foods covering the fields of research and development, manufacturing and distribution.